secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061105
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences reports Q3 net loss $14.4M; partnership with Gilead provides $100M upfront
--------------------------------------------------------------------------------

- Net loss $14.4M ($0.27/sh) vs $23.1M ($0.48/sh) in Q3 2022.
- R&D expenses fell to $10.8M from $18.1M YoY due to trial completions and pipeline discontinuations.
- Cash $46.2M at Sep 30; $100M upfront from Gilead in Oct extends cash runway into 2H 2025.
- Partnership with Gilead includes opt-in rights on current/future pipeline; Gilead contributed two herpesvirus programs.
- Appointed Anuj Gaggar, MD, PhD as CMO; expects four development candidates in clinic by end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/0000950170-23-061105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/asmb-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer